Analia Castro

Mrs. Analia Castro

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2024 in Polymers
Verified
Journal Article
Open access
PDF file
PMPablo Miranda
Pablo Miranda
ACAnalia Castro
Analia Castro
PDPaola Alexandra Diaz Dellavalle
Paola Alexandra Diaz Dellavalle
LMLucia Minini
Lucia Minini
FFFlorencia Ferraro
Florencia Ferraro
HPHelena Pardo
Helena Pardo
We present the development and characterization of a nasal drug delivery system comprised of a thermosensitive mucoadhesive hydrogel based on a mixture of the polymers Poloxamer 407, Poloxamer 188 and Hydroxypropyl-methylcellulose, and the psychedelic drug 5-methoxy-N,-N-dimethyltryptamine. The development relied on a 3 × 3 Box-Behnken experimental design, focusing on optimizing gelification temperature, viscosity and mucoadhesion. The primary objective of this work was to tailor the formulation for efficient nasal drug delivery. This would increase contact time between the hydrogel and the mucosa while preserving normal ciliary functioning. Following optimization, the final formulation underwent characterization through an examination of the in vitro drug release profile via dialysis under sink conditions. Additionally, homogeneity of its composition was assessed using Raman Confocal Spectroscopy. The results demonstrate complete mixing of drug and polymers within the hydrogel matrix. Furthermore, the formulation exhibits sustained release profile, with 73.76% of the drug being delivered after 5 h in vitro. This will enable future studies to assess the possibility of using this formulation to treat certain mental disorders. We have successfully developed a promising thermosensitive and mucoadhesive hydrogel with a gelling temperature of around 32 °C, a viscosity close to 100 mPas and a mucoadhesion of nearly 4.20 N·m.

25 January 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ACAnalia Castro
Analia Castro
ÁPÁlvaro Gustavo Pittini Perez
Álvaro Gustavo Pittini Perez
NBNora Berois
Nora Berois
Ricardo FaccioRicardo Faccio
Ricardo Faccio
PMPablo Miranda
Pablo Miranda
HPHelena Pardo
Helena Pardo
Background/Objectives: The focus of this study was to prepare and characterize docetaxel (DCX)-loaded lipid/polymer hybrid nanoparticles (LPHNps) functionalized with the monoclonal antibody (mAb) Chi-Tn for a potential active targeting approach in lung cancer treatment. Methods: We synthesized DOTAP-PLGA hybrid nanoparticles loaded with DCX and functionalized them with Chi-Tn mAb through a biotin–avidin approach. The physicochemical characterization involved dynamic light scattering, transmission electron microscopy, Raman spectroscopy, and atomic force microscopy. The in vitro and in vivo evaluations encompassed uptake studies, cell viability tests, and the assessment of tumor growth control in a lung cancer model. Results: The nanoparticles featured a hydrophobic PLGA core with 99.9% DCX encapsulation efficiency, surrounded by a DOTAP lipid shell ensuring colloidal stability with a high positive surface charge. The incorporation of PEGylated lipids on their surface helps evade the immune system and facilitate Chi-Tn mAb attachment. The resulting nanoparticles exhibit a spherical shape with monodisperse particle sizes averaging 250 nm, and demonstrate sustained drug release. In vitro uptake studies and viability assays conducted in A549 cancer cells show that the Chi-Tn mAb enhances nanoparticle internalization and significantly reduces cell viability. In vivo studies demonstrate a notable reduction in tumor volume and an increased survival rate in the A549 tumor xenograft mice model when DCX was encapsulated in nanoparticles and targeted with Chi-Tn mAb in comparison to the free drug. Conclusions: Therefore, Chi-Tn-functionalized LPHNps hold promise as carriers for actively targeting DCX to Tn-expressing carcinomas.

13 September 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PMPablo Miranda
Pablo Miranda
LTLuis Ignacio Tartara
Luis Ignacio Tartara
ACAnalia Castro
Analia Castro
PZPatricia Zimet
Patricia Zimet
Ricardo FaccioRicardo Faccio
Ricardo Faccio
HPHelena Pardo
Helena Pardo
Background/Objectives: We report the development of a novel intraocular sustained-release implantable pharmaceutical formulation, designed to be placed in the anterior chamber of the eye after cataract surgery. The device is intended to reduce postoperative inflammation, and to prevent opportunistic bacterial infections that may lead to endophthalmitis. Methods: The implants were produced via hot-melt extrusion, using a twin-screw extruder to process a homogeneous mixture of polylactide-co-glycolic acid, moxifloxacin hydrochloride (MOX HCl) and dexamethasone (DEX). Quality control tests included drug content determination, release rate profile evaluation, and several instrumental characterization techniques (scanning electron microscopy (SEM), confocal Raman microscopy, differential scanning calorimetry, and X-ray diffraction). Long-term and accelerated stability tests were also performed, following ICH guidelines. Sterilization was achieved by exposing samples to gamma radiation. In vivo exploratory studies were carried out in healthy rabbits to evaluate the safety and overall performance of the implantable formulation. Results: In terms of quality control, drug content was found to be homogeneously distributed throughout the implants, and it also met the label claim. In vitro release rate was constant for MOX HCl, but non-linear for DEX, increasing over time. In vivo preliminary tests showed that the inserts completely biodegraded within approximately 20 days. No clinical signs of anterior segment toxic syndrome or statistically significant intraocular pressure differences were found between treatment and control groups. Conclusions: The implants developed in this study can act as sustained-release depots for the delivery of both DEX and MOX HCl, and are biocompatible with ocular structures.

2 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
PMPablo Miranda
Pablo Miranda
LRLuz Daniela Juarez Ruiz
Luz Daniela Juarez Ruiz
LMLuis Leonardo Manlla
Luis Leonardo Manlla
HPHelena Pardo
Helena Pardo
ACAnalia Castro
Analia Castro
LTLuis Ignacio Tartara
Luis Ignacio Tartara
Background/Objectives: Postoperative management after cataract surgery involves topical anti-inflammatory and antimicrobial treatments, whose clinical performance may be affected by adherence, administration technique, and intraocular exposure. This study evaluated a biodegradable poly(lactic-co-glycolic acid) intracameral implant containing moxifloxacin hydrochloride and dexamethasone, designed for intraoperative placement. Methods: Clinical tolerability, anti-inflammatory activity in a uveitis model, and antibacterial performance following a low-inoculum intravitreal challenge with Pseudomonas aeruginosa were evaluated in New Zealand White rabbits. Aqueous humor pharmacokinetic profiles were also assessed in phakic and aphakic eyes. Clinical follow-up included slit-lamp biomicroscopy and intraocular pressure measurements. Concentration–time data were analyzed by means of nonlinear mixed-effects models and model-based simulations. Results: No visible implant material remained four weeks after insertion. A transient pseudo-membrane was observed shortly after implantation in some implanted eyes, but it resolved spontaneously and was not accompanied by clinical inflammatory signs. No sustained increase in intraocular pressure was observed during follow-up. Untreated bacterially challenged eyes rapidly developed severe endophthalmitis, whereas implant-treated eyes showed no clinical evidence of endophthalmitis. In the exploratory uveitis experiment, implant-treated eyes showed lower clinical inflammatory scores and faster recovery than matched eyes without the implant. Model-based simulations suggested persistent dexamethasone exposure through day 30, whereas moxifloxacin reached an early peak and was predominantly below the limit of quantification from day 7 onward. Conclusions: These findings provide preliminary preclinical proof-of-concept evidence supporting the clinical tolerability and pharmacological activity of the implant under the experimental conditions evaluated. The results are hypothesis-generating, should not be extrapolated to clinical safety or efficacy, and do not demonstrate microbiological eradication. Further studies with larger cohorts, pseudophakic models, microbiological and histopathological endpoints, and optimized pharmacokinetic sampling are required.

5 November 2026 in Cancer Letters
Verified
Journal Article
Closed access
SFShunli Fu
Shunli Fu
SSShuo Shan
Shuo Shan
XSXiaoya Shi
Xiaoya Shi
WWWeihua Wang
Weihua Wang
HWHaizhen Wang
Haizhen Wang
HRHe Ren
He Ren

5 November 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PMPablo Miranda
Pablo Miranda
LRLuz Daniela Juarez Ruiz
Luz Daniela Juarez Ruiz
LMLuis Leonardo Manlla
Luis Leonardo Manlla
ACAnalia Castro
Analia Castro
SPSANTIAGO DANIEL PALMA
SANTIAGO DANIEL PALMA
LTLuis Ignacio Tartara
Luis Ignacio Tartara
Background/Objectives: Postoperative management after cataract surgery involves topical anti-inflammatory and antimicrobial treatments, whose clinical performance may be affected by adherence, administration technique, and intraocular exposure. This study evaluated a biodegradable poly(lactic-co-glycolic acid) intracameral implant containing moxifloxacin hydrochloride and dexamethasone, designed for intraoperative placement. Methods: Clinical tolerability, anti-inflammatory activity in a uveitis model, and antibacterial performance following a low-inoculum intravitreal challenge with Pseudomonas aeruginosa were evaluated in New Zealand White rabbits. Aqueous humor pharmacokinetic profiles were also assessed in phakic and aphakic eyes. Clinical follow-up included slit-lamp biomicroscopy and intraocular pressure measurements. Concentration–time data were analyzed by means of nonlinear mixed-effects models and model-based simulations. Results: No visible implant material remained four weeks after insertion. A transient pseudo-membrane was observed shortly after implantation in some implanted eyes, but it resolved spontaneously and was not accompanied by clinical inflammatory signs. No sustained increase in intraocular pressure was observed during follow-up. Untreated bacterially challenged eyes rapidly developed severe endophthalmitis, whereas implant-treated eyes showed no clinical evidence of endophthalmitis. In the exploratory uveitis experiment, implant-treated eyes showed lower clinical inflammatory scores and faster recovery than matched eyes without the implant. Model-based simulations suggested persistent dexamethasone exposure through day 30, whereas moxifloxacin reached an early peak and was predominantly below the limit of quantification from day 7 onward. Conclusions: These findings provide preliminary preclinical proof-of-concept evidence supporting the clinical tolerability and pharmacological activity of the implant under the experimental conditions evaluated. The results are hypothesis-generating, should not be extrapolated to clinical safety or efficacy, and do not demonstrate microbiological eradication. Further studies with larger cohorts, pseudophakic models, microbiological and histopathological endpoints, and optimized pharmacokinetic sampling are required.